Sacubitril-valsartan for the treatment of heart failure effectiveness and value

JAMA Internal Medicine

Volumn 176, Issue 2, 2016, Pages 249-250

  Ollendorf, Daniel A ^a   Sandhu, Alexander T ^b   Pearson, Steven D ^a  

^a INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; SACUBITRIL PLUS VALSARTAN; TETRAZOLE DERIVATIVE;

COST BENEFIT ANALYSIS; ECONOMICS; HEART FAILURE; HUMAN;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; COST-BENEFIT ANALYSIS; HEART FAILURE; HUMANS; TETRAZOLES;

EID: 84957990800     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.7661     Document Type: Short Survey

References (9)

1. Ollendorf DA, Sandhu AT, Chapman R, et al. CardioMEMS HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks. Institute for Clinical and Economic Review. http://ctaf.org/sites/default/files/u148/CHF-Revised-Draft-Report-100915.pdf. Accessed October 10, 2015.
2. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30-41.
3. Feltner C, Jones CD, Cene CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: A systematic review and meta-Analysis. Ann Intern Med. 2014;160(11):774-784.
4. Heidenreich PA, Albert NM, Allen LA, et al; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606-619.
5. Vardeny O,Miller R, Solomon SD. Combined neprilysin and renin-Angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663-670.
6. Entresto pricing information. 2015 Truven Health AnalyticsMicromedex Solutions: REDBOOK; 2015. http://micromedex.com/products/product-suites/clinical-knowledge/redbook. Accessed July 23, 2015.
7. McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
8. Institute for Clinical and Economic Review. Value assessment project: A framework to guide payer assessment of the value of medical services. http://www.icer-review.org/wp-content/uploads/2014/01/Slides-on-value-framework-for-national-webinar1.pdf. Accessed October 19, 2015.
9. US Food and Drug Administration. FDA approved drug products: Entresto. 2015; http://www.fda.gov/Drugs/InformationOnDrugs/ucm457521.htm. Accessed November 20, 2015.